Dr. Greenbaum is a long-time member on the Immune Tolerance Network (ITN) Scientific Advisory Board. The goal of the ITN is to promote therapies for diseases that are caused by a run away immune response. Together, academic, government, and industry researcher collaborate to develop and conduct clinical trials for therapies that promote immune tolerance. We also conduct studies to understand the ways therapies promote immune tolerance and to identify biomarkers associated with immune tolerance. ITN is supprted by the National Institute of Allergy and Infectious Disease.
Dr. Greenbaum’s team has both lead and participated in multiple ITN clinical trials. Some of the most recent include:
- IL-2 and Rapamycin: Completed early phase single site trial showed increase in Tregs but worsening of beta cell function, highlighting narrow therapeutic window of IL-2.
- Extend/Tocilizumab: Completed phase 2 multi-site trial demonstrated safety, but no benefit in preservation of beta cell function in new onset T1D.
- Abate/teplizumab: Completed phase 2 multi-site trial showing preservation of beta cell function in those randomized to teplizumab in new onset T1D
- Designate/siplizumab: beginning enrollment for phase 2 multi-site trial testing safety and preservation of insulin secretion in children and adults within 18 months of diagnosis.
